Dr. Michael Roth's research focuses on understanding the development, regulation and function of dendritic cells and their ability to stimulate effective anti-cancer immunity. Several approaches are being investigated, including the development and testing of novel gene therapy vectors for modulating dendritic cell function and antigen-specificity, the use of cytokines (GM-CSF, IL-4) to activate and expand dendritic cells in situ within the tissues and organs of cancer patients; and the impact that inhaled drugs of abuse (marijuana and cocaine) have on the immune system. This research involves human in vitro studies, model systems and the translation of this basic research into new clinical trials in which immune-based therapy is being used to treat several types of cancer, including lung cancer and prostate cancer.
Selected Cancer-Related Publications:
Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005; 11(15): 5515-25.
Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett S, Roth MD. Increased dendritic cell number and function following continuous in vivo infusion of GM-CSF and IL-4. Blood. 2002; 99(8):2869-2879.
Kiertscher SM, Lou J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol. 2000; 164:1269-1276.
Roth MD, Gitlitz BJ, Kiertscher SM, Park AN, Mendenhall M, Moldawer N, Figlin RA. Granulocyte/macrophage-colony stimulating factor and interleukin-4 enhance the number and antigen-presenting activity of circulating CD14+ and CD83+ cells in cancer patients. Cancer Res. 2000; 60(7):1934-1941.
Kiertscher SM, Roth MD. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4. J Leukoc Biol. 1996; 59:208-218.